Table 4

Impact of NAI therapy starting at 48 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) H275Y virusa

Regimen% mortality on day 12 p.i. (n = 8)% wt loss ± SD on day 5 p.i. (n = 11–12)Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4)
Uninfected/untreated0***−1.2 ± 1.1***Nd
Untreated/infected7516.9 ± 1.53.66 × 106 ± 0.11 × 106
Oseltamivir 5 × 1 mg/kg10018.3 ± 0.72.2 × 106 ± 0.52 × 106
Oseltamivir 5 × 10 mg/kg62.516.5 ± 1.51.46 × 106 ± 0.41 × 106
Peramivir 1 × 90 mg/kg0***7.9 ± 0.9***2.8 × 104 ± 0.7 × 104*
Peramivir 5 × 45 mg/kg0***9.4 ± 1.4**3 × 103 ± 1.8 × 103***
  • a *, P < 0.05; **, P < 0.01; ***, P < 0.001 (versus the untreated group). Statistical significance was determined by using Kaplan-Meier analysis for mortality and the one-way ANOVA test for weight loss and viral lung titers. Nd, not determined. The viral inoculum was 5.7 × 103 PFU.